Removing barriers to tecovirimat treatment for individuals infected with mpox via a novel care delivery model.

Publication date: Jan 01, 2026

This study analyzed the care delivery of a new clinic model designed to provide access to an investigational new drug (IND) during the 2022 mpox outbreak at a single academic quaternary care center. A dedicated tecovirimat referral clinic was created and staffed by a physician associate (PA) trained in IND protocol. The PA assessed patients via telemedicine, managed IND paperwork, prescribed tecovirimat and arranged for its home delivery, and monitored drug tolerance. Of 35 patients referred to the clinic, 17 received tecovirimat. Mean time from clinic referral to first mpox provider visit was 1. 03 days (SD = 1. 90) and from first mpox provider visit to tecovirimat receipt was 0. 22 days (SD = 0. 43). Time before referral was notably longer, with a mean of 9. 37 days (SD = 4. 81) between symptom onset and referral. This clinic provided timely, efficient, specialized care for patients with suspected infection despite the practical barriers of IND protocol.

Semantics

Original Article